“The End of the Golden Weather”: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors
Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma which is often characterised by a pattern of continued relapse after frontline chemoimmunotherapy. Although patients are usually able to regain durable disease control with covalent Bruton’s tyrosine kinase inhibitors (cBTKi) at first...
Saved in:
| Main Authors: | Brian T. Grainger, Chan Y. Cheah |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2024-11-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11822 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mantle cell lymphoma relapsing at the lymphedematous arm.
by: Giuseppina Massini, et al.
Published: (2013-02-01) -
Relapsed Mantle Cell Lymphoma Presenting as “Sister Mary Joseph Nodule”
by: Jennifer E. Vaughn, et al.
Published: (2010-01-01) -
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
by: Raji E Joseph, et al.
Published: (2024-12-01) -
Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
by: Kyoko Miyamoto, et al.
Published: (2024-11-01) -
BTK inhibitors are a possible emerging therapeutic target for gastric cancer
by: José Darío Portillo-Miño, et al.
Published: (2025-03-01)